Prana’s PBT2 features as a top 10 global neuroscience project

Melbourne – Tuesday 19th November, 2013: Prana Biotechnology (ASX:PBT/ NASDAQ:PRAN), a leading innovative drug developer targeting disease modification in neurodegenerative disease, will present at The 2013 Therapeutic Area Partnerships (TAP) meeting in Boston, USA. Since launching eight years ago by Elsevier, TAP has come to be regarded as the industry's premier biopharmaceutical partnering event.

Dr Peter Smith, Prana’s VP Business Development, is presenting at 11.50am on Tuesday, 19th November (US WST).

Elsevier Business Intelligence named clinical drug PBT2 as one of the Top 10 Neuroscience Projects to Watch earlier this year, following its selection by an independent panel. Each year a list is compiled to highlight compounds which address a large, unmet market, strong science and a diversity of indications. @@ PBT2 is a novel, best in class, agent under development for Huntington’s and Alzheimer’s diseases with Phase 2 clinical trial results due for both in the first quarter of 2014.